Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inobrodib + Pomalidomide + Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Phase 2Recruiting
- Sponsor
- CellCentric
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of inobrodib in multiple myeloma (MM), sponsored by CellCentric. Started Jan 2026; status: recruiting.
02
Drugs
inobrodib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07096778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096778.